Core Viewpoint - Mamei Bio's net profit for H1 2025 reached 186 million yuan, a year-on-year increase of 5.21%, while Q2 net profit was 51 million yuan, reflecting a year-on-year decline of 23.08% [1] Financial Performance - H1 2025 net profit: 186 million yuan, up 5.21% year-on-year [1] - Q2 2025 net profit: 51 million yuan, down 23.08% year-on-year [1] - Proposed dividend: 2.5 yuan per share (including tax), with a dividend payout ratio of 53.97% [1] Business Strategy - The company is steadily advancing the differentiated layout and collaborative development of its dual brands, Mamei and PL Lianhuo [1] - Both brands are maintaining good development with steady market penetration [1] - Focus on a big product strategy, with classic products like "Little Gold Needle" continuing to perform well [1] Product Development - The company has a rich portfolio of collagen recombinant protein products and a complete skincare system [1] - In 2025, the investment in Shanghai Moyang Biotechnology Co., Ltd. received a Class III medical device registration certificate from the National Medical Products Administration, highlighting Mamei Bio's forward-looking market positioning [1]